{
    "nctId": "NCT05169567",
    "briefTitle": "Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer",
    "officialTitle": "postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Neoplasm, Neoplasm Metastasis",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 368,
    "primaryOutcomeMeasure": "Progression-Free Survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Have a diagnosis of HR+, HER2- locally advanced or metastatic breast cancer\n* Have radiologic evidence of disease progression or recurrence either\n\n  * On treatment with a CDK4/6 inhibitor with aromatase inhibitor (AI) as initial therapy for advanced disease, or\n  * On/after treatment with a CDK4/6 inhibitor plus endocrine therapy (ET) administered as adjuvant therapy for early stage breast cancer\n* Must be deemed appropriate for treatment with ET\n* If female, have a postmenopausal status by natural or surgical means or by ovarian function suppression\n* Have Response Evaluable Criteria in Solid Tumors (RECIST) evaluable disease (measurable disease and/or nonmeasurable disease)\n* Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group scale (Oken et al. 1982)\n* Have adequate renal, hematologic, and hepatic organ function\n* Must be able to swallow capsules/tablets\n\nExclusion Criteria:\n\n* Have visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosis\n* Have symptomatic or untreated central nervous system metastasis\n* Have received any systemic therapy between disease recurrence/progression and study screening\n* Have received more than 1 line of therapy for advanced or metastatic disease.\n* Have received prior chemotherapy for metastatic breast cancer (MBC)\n* Have received prior treatment with fulvestrant, any investigational estrogen receptor (ER)-directed therapy (including selective ER degraders \\[SERDs\\] and non-SERDs), any phosphatidylinositol 3-kinase (PI3K)-, mammalian target of rapamycin (mTOR)-, or protein kinase B (AKT)-inhibitor",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}